Compare CADL & BBCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CADL | BBCP |
|---|---|---|
| Founded | 1999 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Engineering & Construction |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.8M | 529.1M |
| IPO Year | 2021 | 2017 |
| Metric | CADL | BBCP |
|---|---|---|
| Price | $4.99 | $9.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $17.67 | $13.50 |
| AVG Volume (30 Days) | ★ 1.4M | 87.7K |
| Earning Date | 11-12-2026 | 09-03-2026 |
| Dividend Yield | N/A | ★ 5.32% |
| EPS Growth | ★ 58.62 | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | $125,000.00 | ★ $392,867,000.00 |
| Revenue This Year | N/A | $9.73 |
| Revenue Next Year | N/A | $5.12 |
| P/E Ratio | ★ N/A | $139.71 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.35 | $5.56 |
| 52 Week High | $14.00 | $12.19 |
| Indicator | CADL | BBCP |
|---|---|---|
| Relative Strength Index (RSI) | 25.65 | 39.31 |
| Support Level | $4.62 | $8.89 |
| Resistance Level | $5.51 | $9.64 |
| Average True Range (ATR) | 0.70 | 0.42 |
| MACD | -0.33 | -0.07 |
| Stochastic Oscillator | 1.62 | 3.40 |
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators enables it to deliver concrete placement solutions. The company's operating segments include U.S. Concrete Pumping, U.K. Operations, and U.S. Concrete Waste Management Services, with the majority of revenue generated from the U.S. Concrete Pumping segment. Geographically, it operates in the United States and the United Kingdom, generating majority of its revenue from the United States.